Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 28, 2018
Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple MyelomaManisha Bhutani, David Foureau, Qing Zhang, et al.
Blood Advances|November 22, 2024
MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myelomaManisha Bhutani, Myra Robinson, David Foureau, et al.
Blood Advances|February 20, 2026
Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myelomaShebli Atrash, James Symanowski, Myra Robinson, et al.
Leukemia|February 5, 2025
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myelomaGayathri Ravi, Shambavi Richard, Shaji Kumar, et al.
Blood|April 25, 2025
A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myelomaSarah A Holstein, Shebli Atrash, Hira Mian, et al.
Expert Review of Hematology|May 27, 2026
From episodic assessment to comprehensive assessment: integrating real-world monitoring in relapsed/refractory multiple myelomaCarmel Awadallah, Shebli Atrash, Barry Paul, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRCNagham Youssef, Maha Hameed, Shebli Atrash, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2023
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T ConsortiumDoris K Hansen, Surbhi Sidana, Lauren C Peres, et al.
European Journal of Haematology|May 18, 2026
Condensed vs. Standard Step-Up Dosing Schedule of Talquetamab in Relapsed/Refractory Multiple MyelomaGrace Elsey, James A Davis, Kelley Julian, et al.
Haematologica|October 19, 2023
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experienceHamza Hashmi, Doris K Hansen, Lauren C Peres, et al.
Pageof 9